Ten Emerging Rare Disease Scientists Score Research Grants
While the Eagles football team left Philadelphia to compete in Super Bowl LVII, Uplifting Athletes held its Young Investigator Draft. Inspired by the NFL Draft, the event awards $200,000 in research grants to 10 all-star scientists at the beginning of their careers, and was presented by CSL Behring at Lincoln Financial Field, home of the Philadelphia Eagles.
Uplifting Athletes is a nonprofit organization that connects student-athletes across the country as well as professional athlete ambassadors with their local rare disease community to raise awareness and funds.
The sixth annual Young Investigator Draft includes 10 emerging scientists, each of whom will receive a $20,000 unrestricted grant to support their vital work in rare disease research.
“The members of our 2023 Young Investigator Draft Class represent a group of early-career, diverse researchers who are tremendous assets to the rare disease community,” said Rob Long, executive director of Uplifting Athletes. The 10 scientists that were honored span the research of rare diseases at institutions across the United States.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
